) J. Biol. Chem. 272, 5157-5166]. Serine residue 890 in the C1 cassette is a primary target of PKC phosphorylation and a critical residue in receptor clustering at the membrane. We report herein that the presence of the C1 cassette reduces PKC potentiation and that mutation of Ser-890 significantly restores PKC potentiation. Splicing out or deletion of other C-terminal cassettes singly or in combination had little or no effect on PKC potentiation. Moreover, experiments involving truncation mutants reveal the unexpected finding that NMDARs assembled from subunits lacking all known sites of PKC phosphorylation can show PKC potentiation. These results indicate that PKC-induced potentiation of NMDAR activity does not occur by direct phosphorylation of the receptor protein but rather of associated targeting, anchoring, or signaling protein(s). PKC potentiation of NMDAR function is likely to be an important mode of NMDAR regulation in vivo and may play a role in NMDA-dependent long-term potentiation.
excitatory amino acids ͉ site-directed mutagenesis N -methyl-D-aspartate receptors (NMDARs) mediate slow excitatory transmission in the brain and are thought to play a role in synaptogenesis, formation of neuronal circuitry, synaptic plasticity, and learning and memory (for review, see refs. 1 and 2). NMDARs in mammalian brain are encoded by a gene family comprised of the NR1 and NR2A-D genes (3) . Alternative splicing of NR1 mRNA provides further molecular diversity of NMDARs (for review see ref. 4) . Altogether, eight receptor splice variants are possible, at least seven of which are expressed in the central nervous system. The variants arise through the insertion or deletion of three short exon cassettes in the Nterminal (N1) and C-terminal (C1 and C2) domains. Splicing out of the exon segment encoding C2 removes a stop codon, resulting in an ORF that encodes an unrelated sequence C2Ј at the distal end of the C terminus. NR1 splice variants differ in their patterns of temporal and spatial expression (5, 6) , their pharmacological properties (7) (8) (9) (10) (11) (12) , their ability to be phosphorylated by protein kinases (13, 14) , their efficiency of insertion at the cell surface (15) , and their subcellular localization in heterologous expression systems (16) .
Target sites of kinase-induced phosphorylation have been identified on the NR1, NR2A, and NR2B subunits (13, 14, 17) . Protein kinase C (PKC) phosphorylates serine residues 889, 890, and 896 within the C1 exon of the NR1 subunit; protein kinase A (PKA) phosphorylates serine residue 897 (14) . The relation of PKC-induced phosphorylation of the NR1 and NR2 subunits to PKC-induced potentiation of NMDA channel activity is, however, unclear.
A number of intracellular neuronal proteins, including members of the postsynaptic density 95 (PSD-95͞SAP90) subfamily of membrane-associated putative guanylate kinases, ␣-actinin, calmodulin, neurofilament protein NF-L, and yotiao bind via the C tails of NMDAR to mediate membrane targeting, attachment to the neuronal cytoskeleton, and stabilization of NMDARs (18) (19) (20) (21) (22) (23) (24) (25) (26) . PKC-induced phosphorylation of Ser-890 within the C1 cassette disrupts one or more of these interactions and disperses surface-associated clusters of NR1 subunits (14) .
PKC is likely to be an important regulator of neuronal NMDARs in vivo. The PKC-activating phorbol ester, 12-Otetradecanoyl phorbol-13-acetate (TPA), enhances NMDAelicited currents in trigeminal dorsal horn and hippocampal neurons in slice (27, 28) and in isolated hippocampal neurons in culture (29) . TPA potentiates recombinant NMDARs expressed in Xenopus oocytes (7, 8, (30) (31) (32) and HEK-293 cells (33) . Activation of G protein-coupled receptors, including phosphoinositol-coupled metabotropic glutamate receptors (34, 35) , opioid receptors (36) , and muscarinic receptors (37) , potentiates NMDARs via activation of PKC.
The present study was undertaken to examine the role in PKC-induced potentiation of the NR1 and NR2A C-terminal tails, known to be targets of PKC phosphorylation. Our study shows that splicing in of the C1 cassette, which contains all known sites of phosphorylation on the NR1 subunit, reduces PKC potentiation (see refs. 8, 49, and 50). Mutation of Ser-890, implicated in receptor clustering (16) , partially restores potentiation. Experiments involving truncation mutants reveal the unexpected finding that NMDARs assembled from subunits lacking all known sites of PKC phosphorylation show marked PKC potentiation. These results indicate that PKC-induced potentiation of NMDAR function does not occur by direct phosphorylation of the receptor but rather of associated protein(s) to increase open probability and͞or insertion of new channels into the plasma membrane.
Materials and Methods
Nomenclature. Splice variants of the NR1 subunit are denoted by subscripts indicating presence (1) or absence (0) of alternatively spliced exon cassettes (N1, C1, and C2). NR1 011 (also termed NR1A or NR1-1a) lacks the N1 cassette but contains the C1 and C2 cassettes; NR1 100 (NR1G or NR1-4a) contains N1 but lacks C1 and C2 (4). Subunits lacking C2 contain an unrelated sequence C2Ј. The 33-amino acid sequence between the fourth transmembrane domain (M4) and first C-terminal splice site, C0, is common to all NR1 variants. Residues in the C-terminal Abbreviations: NMDA, N-methyl-D-aspartate; NMDAR, NMDA receptor; PKC and PKA, protein kinase C and A; TPA, 12-O-tetradecanoyl phorbol-13-acetate; M4, fourth transmembrane domain.
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domain were assigned numbers according to their position in NR1 011 .
Expression Constructs. Rat NR1 011 , NR1 010 , NR1 001 , and mouse 1 (rat NR2A homolog) cDNAs were gifts from S. Nakanishi (Kyoto University, Kyoto), V. R. Anantharam (University of Massachusetts, Worcester, MA), and M. Mishina (Niigata University, Niigata, Japan). Other receptor cDNAs were cloned or engineered (7) . cDNAs were linearized with BamHI (wild-type and mutant NR1 100 and NR1 111 ) or NotI (other NR1s and NR2A), and capped mRNAs were synthesized as described (Ambion mMessage mMachine transcription kit; 2 h; 37°C).
Site-Directed Mutagenesis. Serine residues 889, 890, 896, and 897 in the C1 cassette were mutated to alanine singly or altogether. To generate the mutant subunit NR1 100 (⌬C2Ј) (truncated just after C0), the codon for Asp-864 (first residue in C1) was replaced by a stop codon. To generate NR1(⌬C) (''NR1 stop838 ''; ref. 38) , the codon for Arg-839 (six residues after the M4 domain) was replaced by a stop codon. To generate NR2A(⌬C), the codon for Thr-850 (13 residues after M4) was replaced by a stop codon. These truncations removed all serines and threonines downstream from M4 in the two subunits. Mutagenesis was performed with QuikChange (Stratagene), and codon substitutions were confirmed by DNA sequencing.
Electrophysiological Experiments in Xenopus Oocytes. Recombinant NR1͞NR2A receptors were expressed in Xenopus oocytes as described (39) . Selected Stage V and VI oocytes were injected with in vitro transcribed NR1 and NR2A mRNAs (1:2; 50 nl per cell). Samples of mRNA were diluted to achieve expression of receptors with maximal NMDA currents in the range of 100-300 nA. At 3-6 days after injection, responses were recorded in an extracellular solution of Mg 2ϩ -free Ca Ringer's solution as described (12) . Because Ca 2ϩ influx through the NMDAR can cause Ca 2ϩ amplification (12) and inactivation (40) , and activation of chloride channels endogenous to the oocyte (41) and thereby affect measurements of PKC potentiation, experiments were also performed in Ba 2ϩ (nominally Ca 2ϩ -free) Ringer's solution. Recording electrodes contained 3 M KCl; resistance was 0.5-2 M⍀. Currents were elicited by bath application of NMDA (300 M with 10 M glycine) at a holding potential of Ϫ60 mV. For maximal PKC activation, oocytes were incubated in TPA (100 nM; 10 min). Because of variability among batches of oocytes, only batches of oocytes showing an 8-to 12-fold potentiation of NR1 100 ͞NR2A receptor responses were used.
Data Acquisition and Analysis. Current records were filtered at 1 kHz. In Ca 2ϩ Ringer's solution, NMDA currents had an initial peak, followed by a minimum or plateau. Current amplitude was measured at the end of a 20-s agonist application. PKC potentiation is defined as the ratio of NMDA-elicited whole-cell current measured after TPA to that before TPA. Because amplitude of the basal (pre-TPA) NMDA current tended to increase with successive applications of agonist (''run-up''), I control was defined as the response to the first NMDA application. Run-up did not affect the amplitude of the TPApotentiated response and was absent in Ba 2ϩ Ringer's solution. Data are means Ϯ SEM for a minimum of three experiments performed with different oocytes from at least two batches. Statistical significance was assessed by the unpaired Student's t test (P Ͻ 0.05; GRAPHPAD 2.0).
Results
Splicing in of the C1 Splice Cassette Reduces PKC Potentiation. The C1 cassette of the NR1 subunit is known to have target sites of PKC phosphorylation. Thus, we first examined PKC-induced potentiation of pairs of receptors that differed in the presence or absence of C1: NR1 100 ͞NR2A vs. NR1 110 ͞NR2A, NR1 101 ͞NR2A vs. NR1 111 ͞NR2A, NR1 000 ͞NR2A vs. NR1 010 ͞NR2A, and NR1 001 ͞NR2A vs. NR1 011 ͞NR2A ( The presence of the C1 cassette significantly reduced PKC potentiation of NMDA responses for all four pairs of receptors recorded in Ca 2ϩ ( Fig. 1 A and Ringer's solution (Fig. 1B, open circles) . The reduction in potentiation caused by C1 was independent of the presence of the N1, C2, or C2Ј cassettes (Fig. 1B) . Moreover, the degree of potentiation of the NMDAR splice forms did not correlate with basal current amplitudes (Fig. 1C) or with efficiency of expression at the cell surface (15) .
Phosphorylation of Ser-890 in C1 Reduces PKC Potentiation. To examine further the relation between PKC-induced phosphorylation and potentiation, we mutated four serine residues identified as targets of kinase phosphorylation (S889, S890, S896, S897; refs. 13 and 14) , which are contained in the C1 cassette of the NR1 subunit. Altogether, five mutant receptors were examined: a mutant in which all four serines were mutated to alanines and four mutants in which one serine was mutated to alanine. Mutation of all four serines partially rescued PKC potentiation ( Fig. 2 B and C) . Of the possible sites of phosphorylation, only phosphorylation of Ser-890 disrupts receptor clustering at the membrane (14) . The mutant receptor lacking Ser-890 (NR1 111 (S890A)͞NR2A) showed potentiation to 7.9 Ϯ 0.4 (n ϭ 6) times control, a value comparable to the level for the four-serine mutant receptor (Fig. 2C) . Mutation of any one of the other serines (Ser-889, Ser-896, or Ser-897) did not significantly alter the action of TPA, indicating that phosphorylation of these residues is not involved in PKC potentiation. Thus, about half of the effect of the C1 cassette on PKC potentiation is due to phosphorylation of Ser-890.
Alternative Splicing of Exon 22
Modestly Affects PKC Potentiation. To examine specifically the role of the C2 and C2Ј cassettes on PKC potentiation of NMDA responses, we compared pairs of receptors that differed by the presence of C2Ј vs. C2 (Figs. 1 A and 3A) . In C1-containing receptors, splicing in of C2 (replacing C2Ј with C2) resulted in a small but not significant increase in PKC potentiation. In C1-lacking receptors, splicing in of C2 (replacing C2Ј with C2) resulted in a modest decrease in PKC potentiation (significant only for NR1 100 ͞NR2A vs. NR1 101 ͞NR2A receptors in Ca 2ϩ ; P Ͻ 0.05).
To investigate PKC potentiation of a receptor lacking C1, C2, and C2Ј cassettes, we engineered a truncated NR1 receptor, NR1 100 (⌬C2Ј) (Fig. 3B) . The C-terminal domain of the NR1 100 (⌬C2Ј) subunit contained only C0, the initial 33 amino acids after M4. The NR1 100 (⌬C2Ј)͞NR2A mutant had dramatically reduced mean basal current amplitude relative to the corresponding C2Ј or C2-containing receptors, NR1 100 ͞NR2A and NR1 101 ͞NR2A (not illustrated). This finding suggests that specific sequences within C2Ј and C2 enhance basal current amplitude, possibly by attachment to a cytoskeletal protein expressed by the oocyte to promote receptor insertion. In Ba 2ϩ (nominally Ca 2ϩ -free) solution, the NR1 100 (⌬C2Ј)͞NR2A truncation mutant showed significantly increased potentiation relative to that of the NR1 100 ͞NR2A (or NR1 101 ͞NR2A) wild-type receptor (P Ͻ 0.001; no significance in Ca 2ϩ solution; Fig. 3 C  and D) . (Fig. 4) . This truncation mutant lacks the last five amino acid residues of the C0 region of the NR1 subunit, which have been shown to be required for Ca 2ϩ inactivation (38) .
The amplitude of the NMDA-elicited basal current of the NR1⌬C͞NR2A mutant receptor was about two-fold greater than that of the wild-type receptor and did not have the initial peak current followed by desensitization that is a hallmark of the wild-type NMDAR in confirmation of results obtained by Krupp et al. (ref. 38 ; Fig. 4A, first and second rows) . Moreover, the initial current measured in Ca 2ϩ was greater than that measured in Ba 2ϩ and increased during agonist application. In Ca Ringer's solution, the mutant NR1⌬C͞NR2A receptors showed a significantly reduced degree of potentiation relative to that of the wild-type receptor (Fig. 4B) . However, the amplitude of the potentiated current of the truncation mutant did not differ significantly from that of the wild-type receptor, and the increase in basal current observed during agonist application accounts for the apparent decrease in potentiation. These findings also suggest that in the presence of extracellular Ca -free) solution, the C-terminal deletion mutant did not differ significantly from wild-type in either basal current or degree of potentiation (Fig. 4B) .
Truncation of the C-Terminal Domain of NR2A Does Not Alter PKC Potentiation. The C terminus of the NR2A subunit serves as substrate for phosphorylation by PKC (17) , CamKII (42, 43) , and protein tyrosine kinases (44) . A C-terminal deletion mutant [NR2A(⌬C)] was constructed by replacement of the codon for the 13th amino acid residue after M4 by a stop codon; this mutation removes all serines and threonines downstream from M4. The truncated receptor NR1͞NR2A(⌬C) showed virtually the same degree of PKC potentiation as the wild-type receptor (Fig. 4 A and B) . Because the mutant lacks the C terminus of NR2A, we considered whether PKC phosphorylates the NR1 100 (C1, C2-lacking) subunit. In studies involving immunoblotting of NR1 subunits expressed in HEK-293 cells, we failed to detect PKC-induced phosphorylation of sites other than those contained in C1 (n ϭ 3; data not illustrated). Thus, PKC potentiation of NMDAR responses can occur without phosphorylation of the receptor itself.
Truncation of the C-Terminal Tails of NR1 and NR2A Reduces but Does
Not Abolish PKC Potentiation. The double-truncation mutant NR1(⌬C)͞NR2A(⌬C) had a reduced basal current and reduced degree of PKC potentiation relative to that of wild-type or of either single truncation mutant (Fig. 4A, fourth row) . Thus, a significant component of potentiation can be mediated by the C terminus of either subunit, and the effects of the subunits are not additive.
Xenopus oocytes endogenously express a unitary glutamate receptor subunit termed XenU1 (45) and may express an NR2B homolog (12) . To rule out the possibility that the oocyte provides a subunit or subunits that coassemble with rat NR1 to form functional NMDA channels, we carried out an mRNA ''titration'' experiment in which varying amounts of NR2A(⌬C) mRNA were coinjected with a constant amount of NR1 100 per oocyte. In oocytes injected with NR1 100 mRNA alone (i.e., 0 ng NR2A(⌬C)), NMDA elicited a small, desensitizing inward current, suggestive of coassembly of rat NR1 100 with XenU1 or other endogenous subunit to form functional channels. TPA potentiated responses of these receptors by 22-fold. As the ratio of NR2A(⌬C) to NR1 100 mRNA was increased, basal current increased by Ϸ10-fold, indicative of increased assembly and insertion of rat NR1 100 ͞NR2(⌬C) receptors (and͞or higher ratio of NR2 to NR1 per channel); the degree of PKC potentiation decreased to about 8-fold. The increase in basal current indicates that almost all the receptors were rat NR1͞NR2A and that most of the potentiated current was from NR1͞NR2A(⌬C) potentiation of NR1101͞NR2A, NR1100͞NR2A, and NR1100(⌬C2Ј)͞NR2A receptors. In Ca 2ϩ , potentiation of NR1101͞NR2A, NR1100͞NR2A, and NR1100(⌬C2Ј)͞NR2A receptors was to 10.6 Ϯ 0.7 (n ϭ 9), 9.9 Ϯ 0.6 (n ϭ 24), and 11.8 Ϯ 0.1.3 (n ϭ 10) times control (differences not statistically significant). In Ba 2ϩ , potentiation was to 5.3 Ϯ 0.0.7 (n ϭ 9), 5.5 Ϯ 0.5 (n ϭ 19), and 10.8 Ϯ 1.1 (n ϭ 10) times control ( *** , P Ͻ 0.001 vs. each wild-type receptor).
receptors rather than from heteromers assembled from rat NR1 and Xenopus endogenous subunits.
We also examined the effect of increasing the ratio of rat NR2A(⌬C):NR1(⌬C) mRNA. Injection of increasing amounts of NR2A(⌬C) with a constant amount of NR1(⌬C) mRNA (0:1 to 2:1) increased basal current by about 15-fold. In contrast, the degree of PKC potentiation decreased with increasing NR2A(⌬C) mRNA per oocyte over the range of 0:1 to 2:1 from 8-fold to 4-fold. Increasing the ratio of NR2A(⌬C) mRNA to NR1(⌬C) mRNA from 2:1 to 5:1 did not increase basal current further or reduce the degree of potentiation. Thus, the basal and potentiated currents could be attributed to activation of the double-truncation mutant and not of receptors containing a Xenopus subunit.
Discussion
The present study examined the role in PKC potentiation of residues, cassettes, and domains in the C-terminal tails of the NR1 and NR2A subunits. We report herein that splicing out of the C-terminal cassette C1, which contains the only known sites of PKC phosphorylation on the NR1 subunit (13, 14) , increased PKC potentiation of NMDA responses. Mutation of Ser-890, which is implicated in targeting and clustering of NR1 subunits at the membrane (13, 14) , also increased PKC potentiation but less so than splicing out of the entire cassette. Phosphorylation of Ser-890 could reduce potentiation by (i) direct inhibition of NMDAR channel activity or (ii) block of PKC-induced phosphorylation of sites on the NR2 subunits or associated proteins.
Splicing out of the C2 cassette, which is replaced by C2Ј, had little effect on either basal NMDA current or potentiation by PKC. Truncation of the C2Ј (or C2) cassette in an NR1 subunit lacking C1 significantly reduced basal NMDA currents and modestly increased PKC potentiation (relative to that of wildtype NR1 100 ͞NR2A or NR1 101 ͞NR2A receptors) in Ba Ringer's solution). The positive contribution of the C2Ј (or C2) cassette to basal current suggests the possible presence of a recognition sequence or sequences in this region required for binding to the receptor of membraneassociated insertion or anchoring proteins. Although the C2Ј splice cassette contains a PDZ binding consensus sequence (46) , studies involving the yeast two-hybrid system show no evidence for interaction between the NR1 C-terminal tail and either PSD-95 or SAP97 (47) .
The C-terminal domains of the NR1 and NR2A subunits contain all known sites of PKC-, PKA-, and tyrosine kinaseinduced phosphorylation (14, 17) and provide binding sites for a number of intracellular neuronal molecules implicated in receptor localization at the postsynaptic density (see above). Unexpectedly, truncation of the C-terminal domain of either the NR1 or NR2A subunit did not significantly alter PKC potentiation. Our finding that PKC potentiates NR1 100 ͞NR2A(⌬C) receptors (which lack the C1 and C2 exon cassettes) demonstrates that potentiation of NMDAR responses occurs in the absence of any known phosphorylation sites.
PKC potentiation of NR1(⌬C)͞NR2A receptors could occur by direct phosphorylation of the C terminus of NR2A (17) and͞or of a member of the PSD-95͞SAP90 family, which binds via the C-terminal tail of the NR2 subunit. Alternatively, potentiation could occur via activation of a member of the src family of tyrosine kinases, which phosphorylate serine residues Basal currents of NR1͞NR2A(⌬C)and NR1(⌬C)͞NR2A(⌬C) receptors were small relative to those of wild-type receptors. (B) Mean PKC potentiation of mutant and wild-type receptors illustrated in A and of NR1 100(⌬C2Ј)͞NR2A receptors. NR1(⌬C)͞NR2A receptors showed significantly less potentiation than did wild-type NR1 100͞NR2A receptors (which contain the C0 region and C2Ј splice cassette) in Ca 2ϩ Ringer's solution (P Ͻ 0.001) but did not differ significantly in Ba 2ϩ Ringer's solution. The apparent reduction in the degree of potentiation could be accounted for by the larger basal current of the truncation mutant. NR1(⌬C)͞NR2A receptors showed less potentiation than did NR1 100(⌬C2Ј)͞NR2A receptors (which contain the C0 region) in Ca 2ϩ (P Ͻ 0.001) and Ba 2ϩ Ringer's solution (P Ͻ 0.01). Potentiation of NR1100͞NR2A(⌬C) receptors did not differ significantly from that of wild-type receptors. The double-truncation mutant NR1(⌬C)͞NR2A(⌬C) showed significantly less PKC potentiation that did either single truncation mutant [P Ͻ 0.01 vs. NR1(⌬C)͞NR2A and vs. NR1 100 ͞NR2A(⌬C)]. PKC potentiated responses of NR1 100͞NR2A, NR1(⌬C)͞NR2A, NR1100͞NR2A(⌬C), NR1(⌬C)͞NR2A(⌬C), and NR1(⌬C2Ј)͞NR2A receptors to 9.9 Ϯ 0.6 (n ϭ 24), 5.1 Ϯ 0.5 (n ϭ 16), 9.1 Ϯ 0.9 (n ϭ 7), 3.9 Ϯ 0.5 (n ϭ 6), and 11.8 Ϯ 0.1.3 (n ϭ 10) times control in Ca 2ϩ and to 5.5 Ϯ 0.5 (n ϭ 19), 6.2 Ϯ 0.7 (n ϭ 11), 7.2 Ϯ 1.1 (n ϭ 7), 2.8 Ϯ 0.4 (n ϭ 6), and 10.8 Ϯ 1.1 (n ϭ 10) times control in Ba 2ϩ Ringer's solution. *** , P Ͻ 0.001; ** , P Ͻ 0.01; * , P Ͻ 0.05.
in the tail of NR2A. The observation that NMDARs in which both NR1 and NR2A subunits were truncated showed significant but reduced PKC potentiation shows that full potentiation requires the C-terminal tail of either NR1 or NR2A.
Our conclusion that PKC-induced potentiation of NMDARs does not occur via phosphorylation of the receptor subunits is unexpected. Presumably, PKC potentiation occurs via phosphorylation of an as yet unidentified accessory protein. It is possible that this protein leads to interaction with extracellular domains of the receptor subunits, by analogy to the extracellular immediate-early gene product Narp, which promotes insertion and͞or stabilization of ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (48) . Recent studies from our laboratory involving patch-clamp recording of NMDA single channel activity indicate that PKC-induced potentiation involves both an increase in channel open probability and insertion of new channel molecules at the cell surface (J. Y. Lan, A. Skeberdis, T. Jover, R. C. Araneda, Y. Lin, X.Z., R.S.Z., and M.V.L.B., unpublished observations). Findings from the present study indicate that neither mechanism requires direct phosphorylation of the NMDAR protein. PKC potentiation via phosphorylation of an accessory protein is likely to be an important mode of NMDAR regulation in vivo and may be involved in NMDAdependent long-term potentiation (2). 
